- Reaction score
Therapeutic Implications of topical cetrizine 1% in Treatment of Male Androgentic alopecia: A case-controlled study
AbstractBackground: Androgentic alopecia (Androgenetic Alopecia) is the most common form of alopecia in men. Cetrizine, a second generation H1 blocker is known for its anti-inflammatory properties as well as its ability to decrease prostaglandin D2 (PGD2) production. Aim To evaluate the efficacy and tolerability of topical cetirizine in male patients with Androgenetic Alopecia.
Methods: Two groups of 30 patients each (healthy males aged between 22 and 55 years) with different grades of Androgenetic Alopecia classified according to Hamilton Norwood classification were recruited for this study. Group A subjects applied 1 ml of 1% topical cetirizine daily while group B subjects served as controls and were instructed to apply 1 ml of a placebo solution for 6 months.
Results: Dermoscopic assessment revealed significantly higher hair regrowth among the cetirizine-treated group (P<0.001). The patients' satisfaction was significantly higher among the cetirizine-treated group (p < 0.001).
Conclusion: The current study highlights a potential role cetirizine might have in treating Androgenetic Alopecia. It should be noted that studies are lacking in this regard and more randomized and controlled trials are warranted in order to confirm or refute such early findings.
Keywords: Androgenetic alopecia; Cetrizine; Prostaglandin.